

## **Cereno Scientific Participates at GoCo Investor Day on September 9, 2025, in Gothenburg**

**Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will present at GoCo Investor Day hosted by GoCO Health Innovation City and AstraZeneca BioVentureHub. The event is held on Tuesday September 9, 2025.**

Cereno Scientific will present the company at 10:45. A recording of the presentation will be available on our web page after the event.

The event is held between 08:30-14:45 at GoCo House, Entreprenörsstråket 10, Mölndal.

More information and registration can be found on: <https://eu.invajo.com/l/e240rZK71W>.

### **For further information, please contact:**

Tove Bergenholt, Head of IR & Communications  
Email: [tove.bergenholt@cerenoscientific.com](mailto:tove.bergenholt@cerenoscientific.com)  
Phone: +46 73- 236 62 46

### **About Cereno Scientific AB**

Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and pulmonary hypertension.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB

Press release  
September 2, 2025

Cereno Scientific

Carnegie Investment Bank AB, [certifiedadviser@carnegie.se](mailto:certifiedadviser@carnegie.se). More information can be found on [www.cerenoscientific.com](http://www.cerenoscientific.com).